Profilaktika rannikh i pozdnikh serdechno-sosudistykh oslozhneniy u bol'nykh ostrym koronarnym sindromom: rol' statinov
- Authors: Konstantinov V.O1,2, Kukharchik G.A1,2, Kuznetsov A.V1,2, Pavlova Y.R1,2, Kalishevich N.B1,2
-
Affiliations:
- Медицинская академия им. И.И.Мечникова
- Центр профилактики и лечения атеросклероза, Санкт-Петербург
- Issue: Vol 12, No 1 (2010)
- Pages: 62-66
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/93097
- ID: 93097
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
V. O Konstantinov
Медицинская академия им. И.И.Мечникова; Центр профилактики и лечения атеросклероза, Санкт-Петербург
G. A Kukharchik
Медицинская академия им. И.И.Мечникова; Центр профилактики и лечения атеросклероза, Санкт-Петербург
A. V Kuznetsov
Медицинская академия им. И.И.Мечникова; Центр профилактики и лечения атеросклероза, Санкт-Петербург
Ya. R Pavlova
Медицинская академия им. И.И.Мечникова; Центр профилактики и лечения атеросклероза, Санкт-Петербург
N. B Kalishevich
Медицинская академия им. И.И.Мечникова; Центр профилактики и лечения атеросклероза, Санкт-Петербург
References
- American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2002.
- Abdallah M.H, Arnaout S, Karrowni W, Dakik H.A. The management of acute myocardial infarction in developing countries. Int J Cardiol 2006; 111: 189–94.
- The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the plat - let glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488–97.
- The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST - segment elevation. N Engl J Med 2001; 345: 494–502.
- Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease (FRISC II) Investigators: Invasive compared with noninvasive treatment in unstable coronary - artery disease: FRISC II prospective randomized multicenter study. Lancet 1999; 354: 708–15.
- Cannon C.P, Weintraub W.S, Demopoulos L.A, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–87.
- de Winter R.J, Windhausen F, Cornel J.H et al. Early invasive versus selectively invasive management of acute coronary syndromes. N Engl J Med 2005; 353: 1095–104.
- Shephard M.D.S, Hester J, Walmsley R.N, White G.N. Variation in plasma apolipoprotein A-I and B concentrations following myocardial infarction. Ann Clin Biochem 1990; 27: 9–14.
- Ollson A.G, Schwartz G.G, Szarek M et al. High - density lipoprotein, but not low - density lipoprotein cholesterol influence short - term prognosis after acute coronary syndrome: results from the MIRACLE trial. Eur Heart J 2005; 26: 890–6.
- Gordon T, Castelli W.P, Hjortland M.C et al. High - density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62: 707–14.
- Stenestrand U, Wallentin L. For Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430–6.
- Schwartz G.G, Olsson A.G, Ezekowitz M.D et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001; 85: 1711–8.
- de Lemos J.A, Blazing M.A, Wiviott S.D et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16.
- Cannon C.P, Braunwald E, Mc Cabe C.H et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
- Schwartz G.G, Olsson A.G, Szarek M, Sasiela W.J. Characteristics of metabolic syndrome: relation to short - term prognosis and effects of intensive statin therapy after acute coronary syndrome. An analysis of the MIRACL trial. Diabetes Care 2005; 28: 2508–13.
- Olsson A.G, Schwartz G.G, Szarek M et al. Effects of high - dose atorvastatin in patients ≥65 years of age with acute coronary syndrome. Am J Cardiol 2007; 99: 632–5.
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High - dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
- Kinlay S, Schwartz G.G, Olsson A.G et al. High - dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560–6.
- Tsimikas S, Witztum J.L, Miller E.R et al. High - dose atorvastatin reduces plasma levels of oxidized LDL in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110: 1406–12.
- Ridker P.M, Cannon C.P, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20–8.
- Kleeman R, Verschuren L, de Rooij B.J et al. Evidence of atiinflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103: 4188–94.
- Voleti B, Agrawal A. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol 2006; 43: 891–6.
- Verma S, Yeh E.T.H. C-reactive protein and atherotrombosis – Beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1253–R1256.
- La Rosa J.C, Grundy S.M, Waters D.D et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35.
- Pedersen T.R, Faergeman O, Kastelein J.J et al. High - dose atorvastatin vs usual - dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–45.
- Grundy S.M, Cleeman J.I, Merz C.N et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol
Supplementary files
